The Hedgehog Signaling Pathway Emerges as a Pathogenic Target

Margery G. Smelkinson
Biological Imaging Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Abstract

The Hedgehog (Hh) signaling pathway plays an essential role in the growth, development, and homeostasis of many tissues in vertebrates and invertebrates. Much of what is known about Hh signaling is in the context of embryonic development and tumor formation. However, a growing body of evidence is emerging indicating that Hh signaling is also involved in postnatal processes such as tissue repair and adult immune responses. To that extent, Hh signaling has also been shown to be a target for some pathogens that presumably utilize the pathway to control the local infected environment. In this review, we discuss what is currently known regarding pathogenic interactions with Hh signaling and speculate on the reasons for this pathway being a target. We also hope to shed light on the possibility of using small molecule modulators of Hh signaling as effective therapies for a wider range of human diseases beyond their current use in a limited number of cancers.

Keywords

Hedgehog; Gli; influenza; Epstein Barr virus; Hepatitis B and C; HIV; H. pylori; fibrosis; immunity

1. Introduction: Basics of the Hedgehog Signaling Pathway and Its Evolutionary Conservation

The Hedgehog (Hh) family of ligands are secreted signaling molecules essential for embryogenesis and tissue homeostasis in the adult [1–3]. The Hh pathway was originally identified for its developmental role in patterning the Drosophila embryo, and Hh pathway components have subsequently been found to be remarkably conserved between invertebrates and vertebrates where the pathway also plays key roles in several types of cancers, some of which are being treated with drugs that inhibit signaling [3,4].

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Conflicts of Interest: M.G.S. is an author on Patent# US9095579 B2 that relates to treating influenza with small molecule modulators of the Hedgehog signaling pathway.
The Hh ligand acts as a morphogen to control cellular fates by signaling at narrowly defined durations and concentrations [1,2]. In the absence of Hh, the primary transcriptional effector(s)—Cubitus interruptus (Ci) in Drosophila and Gli-2 and Gli-3 in mammals—are tethered to microtubules in the fly or primary cilia in mammals through a transcription factor inhibitory complex (TFIC) (Figure 1A). This complex contains kinases responsible for phosphorylation and consequent partial degradation of Gli/Ci into transcriptional repressors that lack the C-terminal transactivation domain and nuclear export sequences [1–3]. As these shorter protein sequences retain their N-terminal nuclear localization signals, they readily enter the nucleus and inhibit expression of a subset of target genes.

Cells that express the 12-pass transmembrane protein, Patched (ptc), along with coreceptors can receive the Hh ligand and transduce the signal [1,2]. Hh binding to Ptc initiates a phosphorylation cascade of the G-protein coupled receptor-like, seven-pass transmembrane domain protein Smoothened (Smo) resulting in its surface accumulation and a conformational change that is important for triggering downstream effects (Figure 1B). Although there is some divergence between flies and mammals in steps that relay Smo activation to downstream components [2,5], the culmination in all species is a disruption of the TFIC. This leads to the activation of some Hh target genes simply by inhibiting repressor formation. However, further activation via Fused in the fly [6–8] or de-repression by Su(fu) in mammals [9–11] results in the conversion of Gli/Ci into a labile transcription factor that can activate the full range of targets.

One of the key differences between flies and mammals is the redundancy in pathway components [2]. Whereas Drosophila has only one Hh ligand and one primary receptor, mammals have three ligands (Sonic Hedgehog-Shh, Indian Hedgehog-Ihh, and Desert Hedgehog-Dhh) and two primary receptors (Ptch1 and Ptch2). Similarly, Drosophila has only one transcriptional effector, Ci, which can act as both an activator and repressor, whereas mammals have three, Gli1, Gli2, and Gli3, where Gli2 is the primary activator, Gli3 is the primary repressor, and Gli1 is a target gene that acts as an activator in a positive feedback loop [12]. There are also differences in how the message is relayed from Smo to downstream components. Namely, mammalian cells require intracellular transport components housed in primary cilia [13]; this subcellular compartmentalization is not required in Drosophila [5]. Regardless of these differences, the method by which canonical Hh signals as a morphogen in all systems is understood to be by creating precise balances between repressor and activator forms of Gli/Ci, which activate target genes with varying numbers and affinities of transcription factor binding sites [14,15].

Non-canonical pathways have also been described more recently which are independent of Gli activity or independent of Hh activation, suggesting that the influence of the Hh pathway on cellular processes may be far more expansive than originally thought [16]. If this is the case, presumably regulating this pathway provides a broad target to pathogens, such as viruses, that have a limited number of genes and effector avenues for controlling the host environment.
2. Hh Signaling as a Target of Pathogens

While much is known about Hh signaling in embryogenesis [12,17], it has been shown, more recently, that signaling also occurs postnatally in several tissue types such as the skin, lung, gut, and within the haemopoietic and immune systems [18–25]. A clear role has been established for this postnatal signaling in maintaining tissue homeostasis, stem cell maintenance, and regulating haematopoiesis and lymphopoiesis [25–30]. However, more recently, it has also been shown that Hh signaling is activated in response to encounters with pathogens, wounding, and/or damaging agents. As the body of evidence supporting Hh signaling in these latter processes grows, perhaps unsurprisingly, so does the data demonstrating the Hh pathway as a target of several pathogens. Examples of Hh-interacting pathogens are discussed below.

Hepatitis B and C (HBV and HCV, respectively) are major causes of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide [31]. Initial findings by Pereira et al. showed that livers from patients with chronic HBV and HCV infection displayed an increase in hepatocyte production of Hh ligands and an accumulation of Hh-responsive cells with higher levels of pathway activity correlating to more dire outcomes [32]. Complementary studies further confirmed that treatment of liver cells in vitro with the whole HBV replicon or with serum from HCV-infected patients increased expression of Hh targets in a Gli-dependent manner [33,34] and led to pro-fibrotic effects [33]. In the case of HBV, the viral protein causing this effect was revealed to be HBV X (Figure 1B) which increases Gli1 protein stability and promotes nuclear accumulation, an interaction shown likely to be direct through a series of in vitro binding assays [34–36]. While the precise motive by which these viral activities promote infections remains unclear, Choi et al. showed that increasing Hh signaling in liver cells promoted permissiveness for HCV replication, implying the presence of a positive feedback loop between pathway activation and viral production [37].

Hh target genes are also increased in Epstein–Barr virus (EBV)-derived nasopharyngeal carcinoma (NPC) tissue, NPC-derived cell lines, and in EBV infected epithelial cells, in vitro [38]. Further mechanistic studies revealed that the EBV-dependent increase in Gli1 expression correlated to a decrease in expression of Human Leukocyte Antigen, which is involved in presentation of viral antigens to cytotoxic T cells, which may limit the recognition of EBV by the immune system [39]. Hh activity is also upregulated in mice kidneys afflicted with HIV-associated nephropathy and in a human podocyte cell line infected with HIV [40]. This increase was associated with enhanced expression of proliferation and migration markers, loss of kidney filtration barrier function, and increased permeability, which could presumably augment viral dissemination and decrease host defenses, among other effects.

Helicobacter Pylori (H.p.) is a gram-negative bacterium found in the stomach and is the major cause of chronic atrophic gastritis and gastric cancer worldwide [41,42]. During the early stages of H.p. infection, Hh was shown to be upregulated in HCl-secreting parietal cells in an in vivo mouse infection model and in epithelial cell cultures grown in vitro from whole dissociated gastric glands [43–45]. This upregulation of signaling appeared to be due, in part, to the inflammation/repair response as this promoted macrophage recruitment to the
infected area and was dependent upon NFkB induction. Prolonged exposure of H.p., however, resulted in a decrease of Hh expression in the gastric epithelium and an associated loss of parietal cells in the gastric gland in Mongolian gerbils, an established animal model for H. pylori infection, and in patients with H.p.-dependent chronic gastritis analyzed postmortem [46,47]. Eradication of H.p. infection could often restore Hh expression and frequently reversed tumor transformations [48–51]. This decrease of Hh signaling over the course of H.p. infection is partially in response to macrophage secretion of regulatory cytokines [43]. However, it has been also been proposed that H.p.-dependent upregulation of caudal-type homeobox 2 (CXD2), a protein that can bind directly to the promotor of Shh, is responsible for repressing expression, suggesting that this may be an evolved mechanism for regulating Hh pathway activity [52–54].

More recently, we reported that the Hh signaling pathway is also a direct target of the influenza A virus, linking pathway activation to the pathology of the virus [55]. This observation was originally made using Drosophila melanogaster as a model organism to screen for cell non-autonomous activities of disease genes and also an organism where Hh signaling has been shown recently to be linked to innate immunity [56–60].

In larval wing precursors (Figure 2A) expressing the influenza gene Nonstructural protein 1 (NS1), we detected a dramatic increase in expression of the Hh target gene, decapentaplegic (dpp) (Figure 2B), as well as the Dpp target, pMad, and a corresponding increase in distance between the adult wing veins L3 and L4, phenotypes indicative of increased Hh signaling [55,61,62]. Expression of BMP2, the mammalian homologue of dpp, and the Hh target, Ptc1, was also enhanced cell-autonomously in infected mouse lungs, indicating that the effect of NS1 on Hh signaling is conserved between species (Figure 2C,D) [55]. As NS1 is one of 14 proteins encoded by the influenza A virus whose main role is as a virulence factor to interact with host proteins to promote viral growth and maturation, it is perhaps expected that this protein may have evolved to exploit a conserved signaling pathway [63–65].

Using Drosophila, a forward genetic screen was performed to identify point mutations that might disrupt the Hh-dependent activity of NS1. A point mutation was recovered resulting in an alanine to valine substitution at position 122 that reduced this activity in flies and in transfected cells [55]. Interestingly, however, when the A122V mutation was incorporated into a mouse-adapted influenza A virus, it cell-autonomously enhanced expression of some Hh targets in the mouse lung and significantly hastened lethality. These results indicate that, in addition to its multiple intracellular functions, NS1 plays a vital role in activating—but at the same time, mitigating—the activity of a highly conserved signaling pathway during infection. Interestingly, no mutation at position 122 of NS1 has been identified previously in any influenza strain, which may reflect the critical role of NS1 in restraining signaling in order to protect the host. This muting of Hh signaling may be utilized to dampen deleterious effects that could be caused by Hh signaling (discussed below) to ensure optimal viral maturation prior to dissemination.

The precise mechanism by which Hepatitis viruses, HIV, EBV, and H.p. interact with Hh signaling has not been completely elucidated, however, all interactions and often the deleterious effects could be blocked by eliminating Gli [34,39,66] and/or by blocking Hh
signaling with potent inhibitors [33,35,38,40]. Similarly, in flies, NS1-dependent pathway activation was blocked by over-expressing the receptor Ptc (which recruits Hh ligand and prevents it from dissipating to other cells), an RNA interference (RNAi) molecule directed to Ci, or other factors with inhibitory roles in signal transduction [55]. Likewise, constitutively activating signaling using a phosphomimetic form of Smoothened promoted activity. Thus, similar to other viruses, influenza NS1 requires pathway activation to upregulate Hh target genes.

The mechanism by which NS1 modulates Hh signaling was analyzed using the extensive array of genetic and molecular tools available when using Drosophila as a model organism to study disease genes. For example, a series of genetic epistasis experiments and quantitative imaging experiments using Förster resonance energy transfer-Fluorescence lifetime imaging (FRET-FLIM) assays revealed that NS1 interacts directly with the transcriptional mediator, Ci/Gli1, parroting the HBV X/Gli1 interaction [36,55]. Furthermore, this analysis showed that the A122V mutation significantly impeded this interaction. Importantly, pathway activity was not required simply to stabilize the full-length form of Ci and eliminate repressor formation, but additional pathway components with positive roles in signaling were also required for NS1 activity. Taken together, these data suggest that viral proteins likely do not activate the Hh pathway or expression of target genes themselves directly, but rather that Hh signaling is first activated by canonical signaling and then a viral interaction intervenes to alter the readout of the pathway activity. How Hh signaling is initially activated during infection remains an intriguing question.

3. Why Might Hh Signaling Be a Frequent Target for Pathogens?

To ensure efficient use of their genomes, pathogenic interactions are usually established with more centrally connected host proteins so that several processes may be targeted concomitantly. These virulence factors constantly evolve their interface residues, either to evade or to optimize their binding capabilities to host proteins [67]. Thus, some viruses may have evolved the ability to modulate Hh signaling due to its substantial involvement in several processes such as wound healing and the role it plays in immunity.

3.1. Hh Signaling Modulates Wound Repair and Tissue Fibrosis

As Hh signaling has significant roles in tissue homeostasis and remodeling, we speculated that Hh signaling may be activated as a part of a defense mechanism during infection to promote tissue repair (Figure 3). Indeed, a firm role for Hh signaling in wound repair has been established in several cells types such as the lung, skin, and pancreas where damaged areas correlate with Hh activation.

In the lung, acute activation of Shh signaling in epithelial cells was observed upon naphthalene injury, which was strikingly similar to the activation observed during prenatal development [68]. Shh is also upregulated in lung homogenates during hyperoxia-induced injury and recovery [69] and bleomycin administration [70], as well as around damaged airways in lungs chronically exposed to fluorescein isothiocyanate (FITC) [22,71].
In the skin, Asai et al. found that Ptch1 expression is upregulated in wounds in mice and that in vitro stimulation of cultured skin cells with Hh ligand promoted production of angiogenic signals, increased proliferation of fibroblasts, and increased migration, adhesion, and tube formation of endothelial progenitor cells to aid in wound closure [72]. Furthermore, topical gene therapy treatment on wounds using DNA encoding Shh accelerated wound recovery, while commensurate studies showed that wound closure, vascularization, and proliferation were inhibited at wound sites by intraperitoneally injected cylopamine, a potent Smoothened antagonist [21,72–74].

Similarly, Shh signaling in pancreatic fibroblasts is required for tissue repair during the onset of pancreatic cancer and pancreatitis due to a mutation in the proto-oncogene, K-ras, as a deletion of one allele of Gli1 or mice lacking expression of Shh in the pancreatic epithelium significantly impaired tissue remodeling and cytokine expression in this model [75]. This study also confirmed the presence of Ptch1 on the surface of several immune components including peripheral T cells, suggesting that Hh ligand secreted from the damaged areas can activate the local immune network to work simultaneously to repair the tissue. Interestingly, Gli1 also plays a key role in pancreatic tumorigenesis by enhancing expression and activation of Signal transducer and activator of transcription 3 (STAT3) by direct and Hh-dependent upregulation of IL-6 expression [76]. Therefore, a positive feedback loop exists whereby Hh signaling helps initiates tumor formation which, in turn, triggers Hh signaling to assist in tissue repair.

Where repair processes fall short, however, tissue fibrosis can occur, marked by the formation of detrimental scar tissue. Perhaps not surprisingly, there is also a strong link between tissue fibrosis and Hh signaling in several tissues inflicted with chronic ailments, primarily driven by the Hh-dependent activation of epithelial to mesenchymal transition of cells and the resultant excessive extracellular matrix deposition [77]. Pulmonary fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) [78,79], interstitial lung disease [80–82], and usual and nonspecific interstitial pneumonia [83] are all characterized by expression of Shh and Ptch1 in areas of fibrosis. Additionally, Gli1 nlacZ/+ mice show an increased number of Hh-responsive cells in bleomycin-induced fibrosis where overexpression of Shh can further augment damage [84].

Hh ligand secreted by liver cells in response to damage causes cellular differentiation of fibroblasts and myofibroblasts which are critical for normal liver regeneration [37,85,86]. However, similarly to the lung, excessive signaling leads to fibrosis, which can cause cirrhosis and HCC if not controlled [37,77]. Syn et al. demonstrated that Hh upregulates expression of osteopontin (OPN), a cytokine involved in wound healing, in a Nonalcoholic Steathohepatitis-related liver fibrosis, where a reduction in either Hh signaling or OPN reduced fibrogenesis [88]. This was postulated to be through a direct interaction between Gli and Gli-binding sites in the OPN promotor [89]. Moreover, HBV and HCV infections are leading causes of liver fibrosis which is likely mediated through Hh-signaling enhancement (the role of Hh signaling in HBV and HCV pathogenesis is discussed above) [32,33,35].

Hh ligand and target genes, including those involved in extracellular matrix (ECM) production, have also been shown to be upregulated in a mouse model of renal fibrosis.
following injury where protection was provided by cyclopamine treatment or by deficiency in Gli1 [90,91]. Similarly, transgenic zebrafish over-expressing Hh ligands developed pancreatic fibrosis, and pathway components are found upregulated in patients suffering from pancreatitis [92,93]. Correspondingly, Hh-mediated expression of ECM genes were also upregulated in cultured renal cells and in culture-activated pancreatic stellate, both of which showed augmented proliferation and/or migration [91,94].

These data clearly establish the role of Hh signaling in tissue repair processes where unstrained signaling can cause harmful fibrotic outcomes. This aligns with a model in which pathogen-dependent tissue damage causes a Hh-mediated repair response (Figure 3). Some viruses may augment this already active signal to promote irreparable fibrotic damage to ensure viral spread. However, Hh activation at sub-maximal capacity, such as what appears to occur during influenza and in late-stage H.p. infection, may limit formation of fibrotic tissue which may also benefit the pathogen by increasing the time allotted for replication, maturation, and/or dissemination while, at the same time, also maintaining an ample pool of viable hosts available for reinfection.

3.2. Hh Signaling Involved in Immune Pathways and Immune Diseases

The Hh pathway also has postnatal roles in defining the immune response which is conserved from flies to humans, although the relevant signaling output and how it is applied as a defense mechanism differs between vertebrates and invertebrates. In a study conducted in Drosophila by Lee et al., Hedgehog signaling was found to be required as a first line of defense against harmful uracil-secreting pathogens in the gut by triggering the production of microbicidal reactive oxygen species (ROS) [60,95,96]. Flies expressing RNAis directed to several canonical Hh pathway components showed reduced ROS production upon bacterial infection and a consequent higher mortality rate. Exogenous expression of the Hh target gene, Cadherin 99C (Cad99C), however, could rescue this phenotype, and subsequent experiments determined that Cad99C-dependent formation of signaling endosomes stimulated the enzyme, dual oxidase (DUOX), to produce ROS in response to uracil detection.

In mammals, Hh signaling takes a multipronged approach in regulating the immune system by controlling several T-cell features such as differentiation, proliferation, and activity [97,98]. Shh ligands, secreted from thymic epithelial cells to T-cell progenitors, influence cell lineage and proliferation [97]. Prothymocytes undergoing a series of differentiation stages ultimately mature into either helper or cytotoxic T cells defined by the expression of the cell-surface markers, CD4 or CD8, respectively [99]. During this process, thymocytes progress from double-negative (DN) to double-positive (DP) expressing markers, with several intermediate steps in between classified by CD25 and CD44 expression profiles, then on to mature single-positive cells that can then exit the thymus to the bloodstream [100]. Throughout this process, T-cell receptor maturation and selection is occurring via gene rearrangement such that a diverse array of receptors are produced that can recognize foreign peptides [101].

Analysis of thymocyte phenotypes in mouse mutants of Hh pathway components show that Hh signaling is important for regulating T-cell proliferation rates, determining the final
differentiation step between CD4 vs. CD8, controlling various steps throughout the conversion process of double negative cells to single positive cell, as well as modulating the strength of T-cell receptor (TCR) signaling to influence TCR repertoire selection [27–29,102,103]. Additionally, Ihh expression directly in developing DP T-cells themselves is critical for negatively regulating proliferation and differentiation of thymocytes at earlier stages in the developmental process [104]. Ihh is also expressed directly in mature CD8 T-cells and, through an autocrine manner of signaling, is involved in regulating activity by controlling immunological synapse formation and mediating target cell lysis [98]. Thus, both positive [27,80,81,98,103,104] and negative [28,29,104] roles for Hh signaling have been described for these processes, suggesting that there may be a narrow range of signaling that is optimal for proper T-cell maturation and activity and for generating proportional representation of subpopulations.

Direct induction of cytokine expression—secreted factors of immune cells that have an effect on other cells—is another capability of Hh signaling. Peripheral CD4 T-cells retain expression of Hh pathway components and can respond to Hh signaling following TCR-activation [80,81]. Hh signaling can induce clonal expansion of this cell population by enhancing expression of cytokines, such as IL-2, IL-10, and IFNγ, which promote entry into the S-G2 phase of the cell cycle. Additionally, human macrophages stimulated in vitro with recombinant Shh respond by upregulating expression of some cytokines and chemokines, such as IL-6, IL-8, MCP-1, and IL-10, whereas expression of others was reduced in a conditional Hh KO H.p. infection model [105,106]. Shh also induces expression of the profibrotic cytokines, IL-13 and IL-4, in natural killer T-cells during liver fibrosis [107–109].

Consistent with Hh controlling immune cell proliferation and cytokine induction, some autoimmune disorders [110–113] and leukemias [114,115] have been associated with aberrant pathway activation. Allergic asthma is an example of an autoimmune condition where the pathophysiology of the disease is connected to an erroneous immune reaction to aeroallergen inhalation [116]. This disease has been directly linked to Shh production in a murine model where pathway activation results in an over-abundance of conversion of naive T cells to Th2 cells [110]. This occurs through a Hh-dependent upregulation of several target genes that specify Th2 cells’ fates such as the cytokines, IL-4 and IL-1rl1 [30,110]. Thus, while Th2 cells are important for protection against extracellular parasites and tissue remodeling upon damage, they are also involved in the pathogenesis of some allergic and inflammatory diseases [117].

Similarly, influenza infection strongly induced expression of cytokines CXCL-10 and IL6, the latter at least partially by a direct, cell-autonomous interaction between Hh signaling and NS1 [55]. Interestingly, IL6 (along with other Hh target genes discussed above) was present at comparatively higher levels in animals infected with the more pathogenic virus carrying the A122V point mutation in NS1, thus we speculate that the hastened lethality caused by the mutant virus may be due, in part, to a Hh-dependent over-production of cytokines (often called cytokine storms), which have been thought to be the cause of past influenza pandemics [118].
Collectively, these studies indicate that select populations of immune cells are primed to respond to the Hh signal, often resulting in proliferation and an upregulation of a subset of cytokines. Increasing Hh signaling, as occurs in certain tissues during HBV, HCV, EBV, and HIV infection, may help the virus evade the immune response by disrupting the balance of immune components available to extract the infection (Figure 3). In contrast, limiting full pathway activation, as occurs during influenza infection, may suppress the immune response to evade it and/or protect the host from detrimental outcomes, such as cytokine storms [75,76,97].

4. Therapeutic Strategies

Small molecule modulators of Hh signaling have been used in basic research for several years to detect links between signaling and specific phenotypes of interest. Currently, CDC-0449 (Vismodegib) and LDE225 (Sonidegib), both Smoothened inhibitors, and arsenic trioxide (ATO), a Gli1/2 inhibitor, have been approved by the Food and Drug Administration (FDA) to treat basal cell carcinoma (BCC) and certain leukemias, respectively, whereas many others are still in clinical trials (Figure 1B) [3,119,120]. The idea that these approved and yet-to-be-approved molecules might be repurposed to have therapeutic value in humans beyond certain types of cancers is certainly worth exploring [24].

Treatment both in vivo and in vitro with Vismodegib or the Gli inhibitors, Gant-58 and Gant-61, has successfully reversed the detrimental phenotypes caused by several of the ailments mentioned in this review. For example, Vismodegib reduced liver fibrosis and tumor formation in a mouse model of fibrosis-associated HCC [121] and ameliorated early liver fibrosis in a rat model of common bile duct ligation [122]. Vismodegib also reduced the growth of HBV X-expressing tumor xenografts in nude mice and HCC formation in transgenic mice expressing the HBV X protein [35]. Similarly, Gli inhibitors reduced the pro-fibrotic effects and autophagy inhibition in HCV-exposed fibroblasts [33], reduced tumor-sphere formation in several EBV-infected cell lines [38], and decreased the proliferation of Human Papilloma Virus-derived cervical cancer cells [123]. Likewise, ATO was shown to inhibit tumor growth in several types of cancers in both in vitro and in vivo models [124–129].

Thus, it stands to reason that therapeutic uses of FDA-approved molecules that inhibit Hh signaling may be expanded for use as potent inhibitors to treat several pathogenic infections. In contrast to the currently available therapies, such as vaccines and antivirals, which target strain-specific and rapidly-mutating viral proteins, treatments that target highly-conserved host targets may ultimately provide superior and continual protection across a broader spectrum of strains.

Interestingly, HIV-infected cells and tissues appear to be responsive to treatment with both Hh antagonists and agonists—the former directed to infected cells, the latter directed to the local uninfected environment. In the former case, Gli inhibitors were shown to decrease HIV-dependent proliferation and migration of mouse kidney podocytes in vitro [40]. In the latter case, treatment of humanized mice with a Smoothened Agonist reduced leukocyte infiltration into the brain by fortifying the blood–brain barrier, thus limiting the viral niche.
[130,131]. These differences illustrate a circumstance in which the location of the infection (kidney vs brain) can be controlled through contrasting Hh-modulating mechanisms.

These HIV studies reinforce the importance of carefully selecting a relevant treatment since the cellular processes regulated by this signaling pathway are expansive and unforeseeably complex. This may require a combinatorial approach in which several drugs are targeted to different Hh-dependent processes, which may further strengthen or reduce signaling in a context-dependent fashion. This may be possible by using a combination of drugs that target pathway components with both positive and negative roles in signaling. Additionally, defining the precise mechanism in which viral factors interact with the pathway would, no doubt, restrict the search for useful drugs.

5. Summary

The Hh signaling pathway has emerged as a target of several pathogens in recent years, where cases of both pathogen-dependent increases and decreases in pathway activity have been observed. These changes in signaling correlate to an exacerbated detriment to the host and sometimes also as protection, as in the case of influenza. We speculate that the key postnatal roles that Hh signaling plays in wound repair and the immune response are critical features that would be appealing for pathogenic control. Potential new therapies involving Hh inhibitory and stimulatory compounds that disrupt or reverse these interactions could derive from these findings and suggest an important new avenue for further investigation.

Acknowledgments

I would like to thank Ethan Bier for his critical comments, guidance, and advice on this manuscript.

References

1. Pak E, Segal RA. Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. Dev Cell. 2016; 38:333–344. [PubMed: 27554855]
2. Lee RT, Zhao Z, Ingham PW. Hedgehog signalling. Development. 2016; 143:367–372. [PubMed: 26839340]
3. Wu F, Zhang Y, Sun B, McMahon AP, Wang Y. Hedgehog Signaling: From Basic Biology to Cancer Therapy. Cell Chem Biol. 2017; 24:252–280. [PubMed: 28286127]
4. Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980; 287:795–801. [PubMed: 6776413]
5. Huangfu D, Anderson KV. Signaling from Smo to Ci/Gli: Conservation and divergence of Hedgehog pathways from Drosophila to vertebrates. Development. 2006; 133:3–14. [PubMed: 16339192]
6. Ohlmeyer JT, Kalderon D. Hedgehog stimulates maturation of Cubitus interruptus into a labile transcriptional activator. Nature. 1998; 396:749–753. [PubMed: 9874371]
7. Zhou Q, Kalderon D. Hedgehog activates fused through phosphorylation to elicit a full spectrum of pathway responses. Dev Cell. 2011; 20:802–814. [PubMed: 21664578]
8. Alves G, Limbourg-Bouchon B, Tricoire H, Brissard-Zahraoui J, Lamour-Imsard C, Busson D. Modulation of Hedgehog target gene expression by the Fused serine-threonine kinase in wing imaginal discs. Mech Dev. 1998; 78:17–31. [PubMed: 9858670]
9. Wang C, Pan Y, Wang B. Suppressor of fused and Spop regulate the stability, processing and function of Gli2 and Gli3 full-length activators but not their repressors. Development. 2010; 137:2001–2009. [PubMed: 20463034]
10. Humke EW, Dorn KV, Milenkovic L, Scott MP, Rohatgi R. The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins. Genes Dev. 2010; 24:670–682. [PubMed: 20360384]

11. Tukachinsky H, Lopez LV, Salic A. A mechanism for vertebrate Hedgehog signaling: Recruitment to cilia and dissociation of SuFu-Gli protein complexes. J Cell Biol. 2010; 191:415–428. [PubMed: 20956384]

12. Jiang J, Hui CC. Hedgehog signaling in development and cancer. Dev Cell. 2008; 15:801–812. [PubMed: 19081070]

13. Huangfu D, Liu A, Rakeman AS, Murcia NS, Niswander L, Anderson KV. Hedgehog signalling in the mouse requires intraflagellar transport proteins. Nature. 2003; 426:83–87. [PubMed: 14603322]

14. Aberger F, Ruiz IAA. Context-dependent signal integration by the GLI code: The oncogenic load, pathways, modifiers and implications for cancer therapy. Semin Cell Dev Biol. 2014; 33:93–104. [PubMed: 24852887]

15. Winklmayr M, Schmid C, Laner-Plamberger S, Kaser A, Aberger F, Eichberger T, Frischauf A-M. Non-consensus GLI binding sites in Hedgehog target gene regulation. BMC Mol Biol. 2010; 11:2. [PubMed: 20070907]

16. Jenkins D. Hedgehog signalling: Emerging evidence for non-canonical pathways. Cell Signal. 2009; 21:1023–1034. [PubMed: 19399989]

17. Ingham PW, McMahon AP. Hedgehog signaling in animal development: Paradigms and principles. Genes Dev. 2001; 15:3059–3087. [PubMed: 11731473]

18. Outram SV, Varas A, Pepicelli CV, Crompton T. Hedgehog signaling regulates differentiation from double-negative to double-positive thymocyte. Immunology. 2000; 13:187–197. [PubMed: 10981962]

19. Dierks C, Gribic J, Zirlik K, Beigi R, Englund NP, Guo G-R, Veelken H, Engelhardt M, Meteltsmann R, Kelleher JF, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med. 2007; 13:944–951. [PubMed: 17632527]

20. Sacedon R, Diez B, Nunez V, Hernandez-Lopez C, Gutierrez-Frias C, Cejalvo T, Outram SV, Crompton T, Zapata AG, Vicente A, et al. Sonic hedgehog is produced by follicular dendritic cells and protects germinal center B cells from apoptosis. J Immunol. 2005; 174:1456–1461. [PubMed: 15661904]

21. Le H, Kleinerman R, Lerman OZ, Brown D, Galiano R, Gurtner GC, Warren SM, Levine JP, Saadeh PB. Hedgehog signaling is essential for normal wound healing. Wound Repair Regener. 2008; 16:768–773.

22. Stewart GA, Hoyne GF, Ahmad SA, Jarman E, Wallace WA, Harrison DJ, Haslett C, Lamb JR, Howie SE. Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. J Pathol. 2003; 199:488–495. [PubMed: 12635140]

23. Nielsen CM, Williams J, van den Brink GR, Lauwers GY, Roberts DJ. Hh pathway expression in human gut tissues and in inflammatory gut diseases. Lab Invest. 2004; 84:1631–1642. [PubMed: 15502857]

24. Bhardwaj G, Murdoch B, Wu D, Baker DP, Williams KP, Chadwick K, Ling LE, Karanu FN, Bhatia M. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol. 2001; 2:172–180. [PubMed: 11175816]

25. Lau CI, Outram SV, Saldana JI, Furmanski AL, Dessens JT, Crompton T. Regulation of murine normal and stress-induced erythropoiesis by Desert Hedgehog. Blood. 2012; 119:4741–4751. [PubMed: 22461491]

26. Petrova R, Joyner AL. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development. 2014; 141:3445–3457. [PubMed: 25183867]

27. El Andaloussi A, Graves S, Meng F, Mantsal M, Mashayekhi M, Aifantis I. Hedgehog signaling controls thymocyte progenitor homeostasis and differentiation in the thymus. Nat Immunol. 2006; 7:418–426. [PubMed: 16518394]

28. Rowbotham NJ, Furmanski AL, Hager-Theodorides AL, Ross SE, Drakopoulos E, Koufaris C, Outram SV, Crompton T. Repression of hedgehog signal transduction in T-lineage cells increases TCR-induced activation and proliferation. Cell Cycle. 2008; 7:904–908. [PubMed: 18414059]
29. Rowbotham NJ, Hager-Theodorides AL, Cebecauer M, Shah DK, Drakopoulou E, Dyson J, Outram SV, Crompton T. Activation of the Hedgehog signaling pathway in T-lineage cells inhibits TCR repertoire selection in the thymus and peripheral T-cell activation. Blood. 2007; 109:3757–3766. [PubMed: 17227833]

30. Furmanski AL, Saldana JI, Ono M, Sahni H, Paschalidis N, D’Acquisto F, Crompton T. Tissue-derived hedgehog proteins modulate Th differentiation and disease. J Immunol. 2013; 190:2641–2649. [PubMed: 23408837]

31. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: From the perspectives of public health problem to tumor biology. J Gastroenterol. 2009; 44(Suppl 19):96–101. [PubMed: 19148801]

32. De Almeida Pereira T, Witek RP, Syn WK, Choi SS, Bradrick S, Karaca GF, Agboola KM, Jung Y, Omenetti A, Moylan CA, et al. Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest. 2010; 90:1690–1703. [PubMed: 20697376]

33. Granato M, Zompetta C, Vescarelli E, Rizzello C, Cardi A, Valia S, Antonelli G, Marchese C, Torrisi MR, Faggioni A, et al. HCV derived from sera of HCV-infected patients induces profibrotic effects in human primary fibroblasts by activating GLI2. Sci Rep. 2016; 6:30649. [PubMed: 27476557]

34. Kim HY, Cho HK, Hong SP, Cheong J. Hepatitis B virus X protein stimulates the Hedgehog-Gli activation through protein stabilization and nuclear localization of Gli1 in liver cancer cells. Cancer Lett. 2011; 309:176–184. [PubMed: 21726936]

35. Arzumanyan A, Sambandam V, Clayton MM, Choi SS, Xie G, Diehl AM, Yu DY, Feitelson MA. Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. Cancer Res. 2012; 72:5912–5920. [PubMed: 22986746]

36. Jo BB, Jeong MS, Park SY, Cheong J, Jang SB. The Binding of Hepatitis B Virus X Protein to Glioma-Associated Oncogene Homolog 1 and its Biological Characterization In vitro. Appl Biochem Biotechnol. 2011; 165:109. [PubMed: 21468632]

37. Choi SS, Bradrick S, Qiang G, Mostafavi A, Chaturvedi G, Weinman SA, Diehl AM, Jhaveri R. Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. Hepatology. 2011; 54:1580–1590. [PubMed: 21930333]

38. Port RJ, Pinheiro-Maia S, Hu C, Arrand JR, Wei W, Young LS, Dawson CW. Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells. J Pathol. 2013; 231:367–377. [PubMed: 23934731]

39. Pal AD, Banerjee S. Epstein-Barr virus latent membrane protein 2A mediated activation of Sonic Hedgehog pathway induces HLA class Ia downregulation in gastric cancer cells. Virology. 2015; 484:22–32. [PubMed: 26057149]

40. Lan X, Wen H, Cheng K, Plagov A, Shosharti SSM, Malhotra A, Singhal PC. Hedgehog pathway plays a vital role in HIV-induced epithelial-mesenchymal transition of podocyte. Exp Cell Res. 2017; 352:193–201. [PubMed: 28159470]

41. Fuccio L, Eusebi LH, Bazzoli F. Gastric cancer, Helicobacter pylori infection and other risk factors. World J Gastrointest Oncol. 2010; 2:342–347. [PubMed: 21160805]

42. Suerbaum S, Michetti P. Helicobacter pylori infection and other risk factors. World J Gastrointest Oncol. 2010; 2:342–347. [PubMed: 21160805]

43. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347:1175–1186. [PubMed: 12374879]

44. Schumacher MA, Donnelly JM, Engevik AC, Xiao C, Yang L, Kenny S, Varro A, Holland F, Samuelson LC, Zavros Y. Gastric Sonic Hedgehog acts as a macrophage chemottractant during the immune response to Helicobacter pylori. Gastroenterology. 2012; 142:1150–1159. [PubMed: 22285806]

45. El-Zaatari M, Tobias A, Grabowska AM, Kumari R, Scouting PJ, Kaye P, Atherton J, Clarke PA, Powe DG, Watson SA. De-regulation of the sonic hedgehog pathway in the InsGas mouse model of gastric carcinogenesis. Br J Cancer. 2007; 96:1855–1861. [PubMed: 17505514]
46. Suzuki H, Minegishi Y, Nomoto Y, Ota T, Masaoka T, van den Brink GR, Hibi T. Down-regulation of a morphogen (sonic hedgehog) gradient in the gastric epithelium of Helicobacter pylori-infected Mongolian gerbils. J Pathol. 2005; 206:186–197. [PubMed: 15818572]

47. Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Bialek I, Danilewicz M. The immunoeexpression of Shh, Smo and Gli2 in Helicobacter pylori positive and negative gastric biopsies. Pol J Pathol. 2012; 63:25–30. [PubMed: 22535603]

48. Nishizawa T, Suzuki H, Nakagawa I, Minegishi Y, Masaoka T, Iwasaki E, Hibi T. Early Helicobacter pylori eradication restores sonic hedgehog expression in the gastric mucosa of Mongolian gerbils. Digestion. 2009; 79:99–108. [PubMed: 19295210]

49. Shiotani A, Uedo N, Iishi H, Tatsuta M, Ishiguro S, Nakae Y, Kamada T, Haruma K, Merchant JL. Re-expression of sonic hedgehog and reduction of CDX2 after Helicobacter pylori eradication prior to incomplete intestinal metaplasia. Int J Cancer. 2007; 121:1182–1189. [PubMed: 17520681]

50. Nishizawa T, Suzuki H, Masaoka T, Minegishi Y, Iwasaki E, Hibi T. Helicobacter pylori eradication restored sonic hedgehog expression in the stomach. Hepato Gastroenterol. 2007; 54:697–700.

51. Jung DH, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, Lee YC. Helicobacter pylori Eradication on the Prevention of Metachronous Lesions after Endoscopic Resection of Gastric Neoplasm: A Meta-Analysis. PLoS ONE. 2015; 10:e0124725. [PubMed: 25915048]

52. Mutoh H, Hayakawa H, Sashikawa M, Sakamoto H, Sugano K. Direct repression of Sonic Hedgehog expression in the stomach by Cdx2 leads to intestinal transformation. Biochem J. 2010; 427:423–434. [PubMed: 20199401]

53. Barros R, Marcos N, Reis CA, De Luca A, David L, Almeida R. CDX2 expression is induced by Helicobacter pylori in AGS cells. Scand J Gastroenterol. 2009; 44:124–125. [PubMed: 18991163]

54. Matsuda K, Yamauchi K, Matsumoto T, Sano K, Yamaoka Y, Ota H. Quantitative analysis of the effect of Helicobacter pylori on the expressions of SOX2: CDX2: MUC2: MUC5AC, MUC6: TFF1: TFF2: and TFF3 mRNAs in human gastric carcinoma cells. Scand J Gastroenterol. 2008; 43:25–33. [PubMed: 18938748]

55. Smelkinson MG, Guichard A, Teijaro JR, Malur M, Loureiro ME, Jain P, Ganesan S, Zúñiga EI, Krug RM, Oldstone MB, et al. Influenza NS1 directly modulates Hedgehog signaling during infection. PLoS Pathog. 2017; 13:e1006588. [PubMed: 28837667]

56. Bier E, Guichard A. Deconstructing host-pathogen interactions in Drosophila. Dis Model Mech. 2012; 5:48–61. [PubMed: 21979942]

57. Bier E. Drosophila, the golden bug, emerges as a tool for human genetics. Nat Rev Genet. 2005; 6:9–23. [PubMed: 15630418]

58. Reiter LT, Potocki L, Chien S, Gribskov M, Bier E. A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Res. 2001; 11:1114–1125. [PubMed: 11381037]

59. Hughes TT, Allen AL, Bardin JE, Christian MN, Daimon K, Dozier KD, Hansen CL, Holcomb LM, Ahlander J. Drosophila as a genetic model for studying pathogenic human viruses. Virology. 2012; 423:1–5. [PubMed: 22177780]

60. Lee KA, Kim B, Bhn J, Kim DH, Yu H, Kim EK, Kim SH, Ryu JH, Hwang D, Lee WJ. Bacterial uracil modulates Drosophila DUOX-dependent gut immunity via Hedgehog-induced signaling endosomes. Cell Host Microbe. 2015; 17:191–204. [PubMed: 25639794]

61. Bietsch B, Sturtevant MA, Bier E. Boundaries in the Drosophila wing imaginal disc organize vein-specific genetic programs. Development. 1998; 125:4245–4257. [PubMed: 9753679]

62. St Johnston RD, Hoffmann FM, Blackman RK, Segal D, Grimala R, Padgett RW, Irick HA, Gelbart WM. Molecular organization of the decapentaplegic gene in Drosophila melanogaster. Genes Dev. 1990; 4:1114–1127. [PubMed: 2120113]

63. Lamb, RA., Krug, RM. Othromyxoviridae: The viruses and their replication. In: Knipe, DM., Howley, PM., editors. Fundamental Virology. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2001.

64. Hale BG, Randall RE, Ortin J, Jackson D. The multifunctional NS1 protein of influenza A viruses. J Gen Virol. 2008; 89:2359–2376. [PubMed: 18796704]
65. Marc D. Influenza virus non-structural protein NS1: Interferon antagonism and beyond. J Gen Virol. 2014; 95:2594–2611. [PubMed: 25182164]
66. El-Zaatari M, Kao JY, Tessier A, Bai L, Hayes MM, Fontaine C, Eaton KA, Merchant JL. Gli1 deletion prevents Helicobacter-induced gastric metaplasia and expansion of myeloid cell subsets. PLoS ONE. 2013; 8:e58935. [PubMed: 23520544]
67. Zheng LL, Li C, Ping J, Zhou Y, Li Y, Hao P. The domain landscape of virus-host interactomes. Biomed Res Int. 2014; 2014:867235. [PubMed: 24991570]
68. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003; 422:313–317. [PubMed: 12629553]
69. Pogach MS, Cao Y, Millien G, Ramirez MI, Williams MC. Key developmental regulators change during hyperoxia-induced injury and recovery in adult mouse lung. J Cell Biochem. 2007; 100:1415–1429. [PubMed: 17167788]
70. Moshai EF, Wemeau-Stervinou L, Cigna N, Brayer S, Somme JM, Crestani B, Mailleux AA. Targeting the hedgehog-glioma-associated oncogene homolog pathway inhibits bleomycin-induced lung fibrosis in mice. Am J Respir Cell Mol Biol. 2013; 51:11–25. [PubMed: 24450438]
71. Fisher CE, Ahmad SA, Fitch PM, Lamb JR, Howie SE. FITC-induced murine pulmonary inflammation: CC10 up-regulation and concurrent Shh expression. Cell Biol Int. 2005; 29:868–876. [PubMed: 16150617]
72. Asai J, Takenaka H, Kusano BF, Luedemann C, Curry C, Eaton E, Iwakura A, Tsutumi Y, Hamada H, et al. Topical sonic hedgehog gene therapy accelerates wound healing in diabetes by enhancing endothelial progenitor cell-mediated microvascular remodeling. Circulation. 2006; 113:2413–2424. [PubMed: 16702471]
73. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002; 16:2743–2748. [PubMed: 12414725]
74. Luo JD, Hu TP, Wang L, Chen MS, Liu SM, Chen AF. Sonic hedgehog improves delayed wound healing via enhancing cutaneous nitric oxide function in diabetes. Am J Physiol Endocrinol Metab. 2009; 297:E525–E531. [PubMed: 19531636]
75. Mathew E, Collins MA, Fernandez-Barrena MG, Holtz AM, Wan Y, Hogan JO, Tata Z, Allen BL, Fernandez-Zapico ME, Di Magliano MP. The transcription factor GLI1 modulates the inflammatory response during pancreatic tissue remodeling. J Biol Chem. 2014; 289:27727–27743. [PubMed: 25104358]
76. Mills LD, Zhang Y, Marler RJ, Herreros-Villanueva M, Zhang L, Almada LL, Couch F, Wetmore C, Di Magliano MP, Fernandez-Zapico ME. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. J Biol Chem. 2013; 288:11786–11794. [PubMed: 23482563]
77. Hu L, Lin X, Lu H, Chen B, Bai Y. An overview of hedgehog signaling in fibrosis. Mol Pharmacol. 2015; 87:174–182. [PubMed: 25390543]
78. Bolanos AL, Milla CM, Lira JC, Ramirez R, Checa M, Barrera L, García-Alvarez J, Carbajal V, Becerril C, Gaxiola M, et al. Role of Sonic Hedgehog in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012; 303:L978–L990. [PubMed: 23023967]
79. Cigna N, Moshai EF, Brayer S, Marchal-Somme J, Wemeau-Stervinou L, Fabre A, Mal H, Lesèche G, Dehoux M, Soler P, et al. The hedgehog system machinery controls transforming growth factor-beta-dependent myofibroblastic differentiation in humans: Implication in idiopathic pulmonary fibrosis. Am J Pathol. 2012; 181:2126–2137. [PubMed: 23031257]
80. Lowrey JA, Stewart GA, Lindey S, Hoyne GF, Dallman MJ, Howie SE, Lamb JR. Sonic hedgehog promotes cell cycle progression in activated peripheral CD4(+) T lymphocytes. J Immunol. 2002; 169:1869–1875. [PubMed: 12165511]
81. Stewart GA, Lowrey JA, Wakelin SJ, Fitch PM, Lindey S, Dallman MJ, Lamb JR, Howie SE. Sonic hedgehog signaling modulates activation of and cytokine production by human peripheral CD4+ T cells. J Immunol. 2002; 169:5451–5457. [PubMed: 12421920]
82. Fitch PM, Howie SE, Wallace WA. Oxidative damage and TGF-beta differentially induce lung epithelial cell sonic hedgehog and tenascin-C expression: Implications for the regulation of lung
remodelling in idiopathic interstitial lung disease. Int J Exp Pathol. 2011; 92:8–17. [PubMed: 21039988]

83. Coon DR, Roberts DJ, Loscertales M, Kradin R. Differential epithelial expression of SHH and FOXF1 in usual and nonspecific interstitial pneumonia. Exp Mol Pathol. 2006; 80:119–123. [PubMed: 16448649]

84. Liu L, Kugler MC, Loomis CA, Samdani R, Zhao Z, Chen GJ, Brandt JP, Brownell I, Joyner AL, Rom WN, et al. Hedgehog signaling in neonatal and adult lung. Am J Respir Cell Mol Biol. 2013; 48:703–710. [PubMed: 23371063]

85. Jung Y, Diehl AM. Non-alcoholic steatohepatitis pathogenesis: Role of repair in regulating the disease progression. Dig Dis. 2010; 28:225–228. [PubMed: 20460916]

86. Omenetti A, Diehl AM. Hedgehog signaling in cholangiocytes. Curr Opin Gastroenterol. 2011; 27:268–275. [PubMed: 21423008]

87. Ochoa B, Syn WK, Delgado I, Karaca GF, Jung Y, Wang J, Zubiaga AM, Fresneda O, Omenetti A, Zdanowicz M, et al. Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology. 2010; 51:1712–1723. [PubMed: 20432255]

88. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology. 2011; 53:106–115. [PubMed: 20967826]

89. Das S, Harris LG, Metge BJ, Liu S, Riker AI, Samant RS, Shevde LA. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J Biol Chem. 2009; 284:22888–22897. [PubMed: 19556240]

90. Fabian SL, Penchev RR, Jacques BS, Rao AN, Sipila P, West KA, McMahon AP, Humphreys BD. Hedgehog-Gli Pathway Activation during Kidney Fibrosis. Am J Pathol. 2012; 180:1441–1453. [PubMed: 22342522]

91. Ding H, Zhou D, Hao S, Zhou L, He W, Nie J, Hou FF, Liu Y. Sonic Hedgehog Signaling Mediates Epithelial-Mesenchymal Communication and Promotes Renal Fibrosis. J Am Soc Nephrol. 2012; 23:801–813. [PubMed: 22302193]

92. Kayed H, Kleeff J, Keleg S, Buchler MW, Friess H. Distribution of Indian hedgehog and its receptors patched and smoothed in human chronic pancreatitis. J Endocrinol. 2003; 178:467–478. [PubMed: 12967338]

93. Jung IH, Jung DE, Park YN, Song SY, Park SW. Aberrant Hedgehog ligands induce progressive pancreatic fibrosis by paracrine activation of myofibroblasts and ductular cells in transgenic zebrafish. PLoS ONE. 2011; 6:e27941. [PubMed: 22164219]

94. Shinozaki S, Ohnishi H, Hama K, Kita H, Yamamoto H, Osawa H, Sato K, Tamada K, Mashima H, Sugano K. Indian hedgehog promotes the migration of rat activated pancreatic stellate cells by increasing membrane type-1 matrix metalloproteinase on the plasma membrane. J Cell Physiol. 2008; 216:38–46. [PubMed: 18286338]

95. Bier E, Nizet V. Hedgehog: Linking uracil to innate defense. Cell Host Microbe. 2015; 17:146–148. [PubMed: 25674980]

96. Lee KA, Kim B, You H, Lee WI. Uracil-induced signaling pathways for DUOX-dependent gut immunity. Fly. 2015; 9:115–120. [PubMed: 26655037]

97. Crompton T, Outram SV, Hager-Theodorides AL. Sonic hedgehog signalling in T-cell development and activation. Nat Rev Immunol. 2007; 7:726–735. [PubMed: 17690714]

98. De la Roche M, Ritter AT, Angus KL, Dinsmore C, Earnshaw CH, Reiter JF, Griffiths GM. Hedgehog signaling controls T cell killing at the immunological synapse. Science. 2013; 342:1247–1250. [PubMed: 24311692]

99. Godfrey DI, Zlotnik A. Control points in early T-cell development. Immunol Today. 1993; 14:547–553. [PubMed: 7903854]

100. Haks MC, Oosterwegel MA, Blom B, Spits HM, Kruisbeek AM. Cell-fate decisions in early T cell development: Regulation by cytokine receptors and the pre-TCR. Semin Immunol. 1999; 11:23–37. [PubMed: 9950750]

101. Borowski C, Martin C, Gounari F, Haughn L, Aifantis I, Grassi F, von Boehmer H. On the brink of becoming a T cell. Curr Opin Immunol. 2002; 14:200–206. [PubMed: 11869893]
102. Shah DK, Hager-Theodorides AL, Outram SV, Ross SE, Varas A, Crompton T. Reduced thymocyte development in sonic hedgehog knockout embryos. J Immunol. 2004; 172:2296–2306. [PubMed: 14764698]

103. Hager-Theodorides AL, Dessens JT, Outram SV, Crompton T. The transcription factor Gli3 regulates differentiation of fetal CD4–CD8–double-negative thymocytes. Blood. 2005; 106:1296–1304. [PubMed: 15855276]

104. Outram SV, Hager-Theodorides AL, Shah DK, Rowbotham NJ, Drakopoulou E, Ross SE, Lanske B, Dessens JT, Crompton T. Indian hedgehog (Ihh) both promotes and restricts thymocyte differentiation. Blood. 2009; 113:2217–2228. [PubMed: 19109233]

105. Wakelin SJ, Forsythe JL, Garden OJ, Howie SE. Commercially available recombinant sonic hedgehog up-regulates Ptc and modulates the cytokine and chemokine expression of human macrophages: An effect mediated by endotoxin contamination? Immunobiology. 2008; 213:25–38. [PubMed: 18207025]

106. Marwaha S, Schumacher MA, Zavros Y, Eghbalnia HR. Crosstalks between cytokines and Sonic Hedgehog in Helicobacter pylori infection: A mathematical model. PLoS ONE. 2014; 9:e111338. [PubMed: 25364910]

107. Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, Wynn TA. IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol. 1999; 162:920–930. [PubMed: 9916716]

108. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006; 12:99–106. [PubMed: 16327802]

109. Syn WK, Witek RP, Curbishley SM, Jung Y, Choi SS, Enrich B, Omenetti A, Agboola KM, Fearing CM, Tilg H. Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur J Immunol. 2009; 39:1879–1892. [PubMed: 19544307]

110. Standing AS, Yanez DC, Ross R, Crompton T, Furmanski AL. Frontline Science: Shh production and Gli signaling is activated in vivo in lung, enhancing the Th2 response during a murine model of allergic asthma. J Leukoc Biol. 2017

111. Qin S, Sun D, Li H, Li X, Pan W, Yan C, Tang R, Liu X. The Effect of SHH-Gli Signaling Pathway on the Synovial Fibroblast Proliferation in Rheumatoid Arthritis. Inflammation. 2016; 39:503–512. [PubMed: 26552406]

112. Samanta J, Grund EM, Silva HM, Lafaille JJ, Fishell G, Salzer JL. Inhibition of Gli1 mobilizes endogenous neural stem cells for remyelination. Nature. 2015; 526:448–452. [PubMed: 26416758]

113. Seifert T, Bauer J, Weissert R, Fazekas F, Storch MK. Differential expression of sonic hedgehog immunoreactivity during lesion evolution in autoimmune encephalomyelitis. J Neuropathol Exp Neurol. 2005; 64:404–411. [PubMed: 15892298]

114. Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S, Kawano Y, Miyanishi K, Sato Y, Nitsu Y, et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci. 2009; 100:948–955. [PubMed: 19245435]

115. Dagklis A, Pauwels D, Lahortiga I, Geerdens E, Bittoun E, Cauwelier B, Tousseyn T, Uyttebroeck A, Maertens J, Verhoeof G, et al. Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia. Haematologica. 2015; 100:e102–e105. [PubMed: 25527561]

116. Nhu QM, Aceves SS. Tissue Remodeling in Chronic Eosinophilic Esophageal Inflammation: Parallels in Asthma and Therapeutic Perspectives. Front Med. 2017; 4:128.

117. Potter CW, Jennings R. A definition for influenza pandemics based on historical records. J Infect. 2011; 63:252–259. [PubMed: 21632115]

118. Aditya S, Rattan A. Vismodegib: A smoothed inhibitor for the treatment of advanced basal cell carcinoma. Indian Dermatol Online J. 2013; 4:365–368. [PubMed: 24350028]

119. Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothed and GLI Inhibitors. Cancers. 2016; 8:22.

J Dev Biol. Author manuscript; available in PMC 2017 December 04.
121. Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, Moylan C, Venkatraman T, Feuerlein S, Syn WK, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS ONE. 2011; 6:e23943. [PubMed: 21912653]

122. Pratap A, Panakanti R, Yang N, Eason JD, Mahato RI. Inhibition of endogenous hedgehog signaling protects against acute liver injury after ischemia reperfusion. Pharm Res. 2010; 27:2492–2504. [PubMed: 20737284]

123. Samarzija I, Beard P. Hedgehog pathway regulators influence cervical cancer cell proliferation, survival and migration. Biochem Biophys Res Commun. 2012; 425:64–69. [PubMed: 22820185]

124. Cai X, Yu K, Zhang L, Li Y, Li Q, Yang Z, Shen T, Duan L, Xiong W, Wang W. Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002. OncoTargets Ther. 2015; 8:877–883.

125. Kerl K, Moreno N, Holsten T, Ahlfeld J, Mertins J, Hotfilder M, Kool M, Bartelheim K, Schleicher S, Handgretinger R, et al. Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. Int J Cancer. 2014; 135:989–995. [PubMed: 24420698]

126. Nakamura S, Nagano S, Nagao H, Ishidou Y, Yokouchi M, Abematsu M, Yamamoto T, Komiya S, Setoguchi T. Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation. PLoS ONE. 2013; 8:e69466. [PubMed: 23861973]

127. Yang D, Cao F, Ye X, Zhao H, Liu X, Li Y, Shi C, Wang H, Zhou J. Arsenic trioxide inhibits the Hedgehog pathway which is aberrantly activated in acute promyelocytic leukemia. Acta Haematol. 2013; 130:260–267. [PubMed: 23867347]

128. You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2014; 147:508–516. [PubMed: 24094913]

129. Bansal N, Farley NJ, Wu L, Lewis J, Youssoufiyan H, Bertino JR. Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling. Mol Cancer Ther. 2015; 14:23–30. [PubMed: 25381261]

130. Singh VB, Singh MV, Gorantla S, Poluektova LY, Maggirwar SB. Smoothened Agonist Reduces Human Immunodeficiency Virus Type-1-Induced Blood-Brain Barrier Breakdown in Humanized Mice. Sci Rep. 2016; 6:26876. [PubMed: 27241024]

131. Singh VB, Singh MV, Piekna-Przybylska D, Gorantla S, Poluektova LY, Maggirwar SB. Sonic Hedgehog mimetic prevents leukocyte infiltration into the CNS during acute HIV infection. Sci Rep. 2017; 7:9578. [PubMed: 28852071]
Figure 1.
Schematic illustration of Hh signaling and how pathogens may modify pathway activity. (A) In the absence of Hh ligand, the receptor Ptc inhibits Smo activation. Ci/Gli is retained in the cytoplasm tethered to microtubules (in flies) or primary cilia (in mammals) through a complex of several proteins, simplistically termed here as “transcription factor inhibitory complex” (TFIC). This complex promotes Ci/Gli phosphorylation, which results in partial proteolysis to a repressor form that can readily enter the nucleus and repress expression of some Gli targets. (B) When Hh ligand binds to Ptc, inhibition upon Smo is relieved and the C-terminus of Smo is phosphorylated which promotes the release of Ci/Gli from the TFIC. The activated form of Gli/Ci can enter the nucleus and activate expression of Hh targets. Examples of canonical Gli target genes as well as those involved specifically in proliferation, immunity, and migration are given. Helicobacter Pylori (H.p.) has been proposed to act, in part, by repressing expression of the Hh ligand. Influenza NS1 and HBV X protein have been proposed to interact directly with Gli/Ci, but the precise mechanism by which they affect transcriptional activity has not been fully elucidated. The diagram also shows the pathway components which can be inhibited by FDA-approved small molecules: Vismodegib and Sonidegib inhibit the activity of Smo, whereas arsenic trioxide (ATO) inhibits the activity of Gli1/2.
Figure 2.
Influenza NS1 increases Hh target gene expression in *Drosophila* and mice. (A) Schematic diagram of a *Drosophila* wing imaginal disc with the anterior/posterior (A/P) border, the domain where Hh signaling is active, demarcated in red. The dashed box represents the area of the disc that was imaged in B. (B) Influenza NS1, expressed from a transgene in the wing imaginal disc, increases expression of the Hh target gene reporter, *dpp-lacZ*, at the A/P border compared with a disc with no transgene (no tg). (C,D) Infected mouse lungs show a cell-autonomous increase in expression of the Hh targets, BMP2 (C) and Ptch1 (D) compared with uninfected lungs. Target proteins are in green, NS1 is in red.
Figure 3.
Hypothesis for what occurs during a pathogenic interaction with Hh signaling. Pathogens that cause damage to the host tissue promote activation of Hh signaling due to the key roles it plays in repair processes and immunity (green boxes). If not regulated properly, these cellular processes can cause fibrosis and an imbalanced immune response, respectively (red boxes). Pathogens, such as Influenza, EBV, HBC, HCV, HIV, and H.p., have been shown to directly modulate pathway activity once signaling is activated and may do so in order to exacerbate or restrain these detrimental outcomes.